INmune Bio, Inc.INMBNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
69.75%
↑ 249% above average
Average (36q)
-46.83%
Historical baseline
Range
High:77.60%
Low:-620.56%
Volatility
-1490.9%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 69.75% |
| Q2 2025 | -148.07% |
| Q1 2025 | -4.63% |
| Q4 2024 | 22.94% |
| Q3 2024 | -24.54% |
| Q2 2024 | 10.46% |
| Q1 2024 | -31.48% |
| Q4 2023 | 1.75% |
| Q3 2023 | -33.02% |
| Q2 2023 | 0.19% |
| Q1 2023 | -13.84% |
| Q4 2022 | 24.20% |
| Q3 2022 | -16.52% |
| Q2 2022 | 1.39% |
| Q1 2022 | 28.26% |
| Q4 2021 | -0.10% |
| Q3 2021 | -37.64% |
| Q2 2021 | -44.11% |
| Q1 2021 | -41.73% |
| Q4 2020 | 33.41% |
| Q3 2020 | -128.67% |
| Q2 2020 | -0.72% |
| Q1 2020 | 10.29% |
| Q4 2019 | 24.37% |
| Q3 2019 | -620.56% |
| Q2 2019 | 77.60% |
| Q1 2019 | -1.65% |
| Q4 2018 | -22.08% |
| Q3 2018 | 75.06% |
| Q2 2018 | -116.94% |
| Q1 2018 | -564.95% |
| Q4 2017 | -38.96% |
| Q3 2017 | -86.67% |
| Q2 2017 | -38.13% |
| Q1 2017 | -41.07% |
| Q4 2016 | -56.24% |
| Q3 2016 | 0.00% |